Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should be counselled about this risk Patient safety advice for those using GLP-1 receptor agonists includes: Report persistent nausea, vomiting, or abdominal pain to your GP promptly Stop treatment and seek urgent medical care if you develop severe, persistent abdominal pain that may suggest pancreatitis Maintain adequate hydration, especially during initial treatment and if experiencing vomiting or diarrhoea Monitor for signs of gallbladder problems (sustained upper right abdominal pain, fever, jaundice) Patients with diabetes should monitor blood glucose levels closely, particularly when starting treatment or adjusting doses Inform healthcare providers of all medications to assess interaction risks Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app Pregnant women or those planning pregnancy should not use GLP-1 receptor agonists
Take it daily for at least 8 weeks before you decide whether its working
Though facial melanoma is commonly found in the elderly population, melanomas occurring in special locations were not found in the group of patients with NMSC, except for 1 case of acral melanoma
Vitamin B12 and folate are key for DNA, helping red blood cells grow and mature
These statements reflect company marketing language and have not been independently verified as evidence of weight-loss or GLP-1 effects
